Premium
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
Author(s) -
Müller Thomas,
Woitalla Dirk,
Goetze Oliver,
Erdmann Christoph
Publication year - 2008
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22176
Subject(s) - entacapone , carbidopa , catechol o methyl transferase , chemistry , benserazide , levodopa , pharmacology , parkinson's disease , absorption (acoustics) , bioavailability , sodium , medicine , biochemistry , disease , allele , physics , acoustics , gene , organic chemistry
Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐ O ‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD derivatives. LD metabolism correlates to the one of 13 C‐sodium‐octanoate, which is employed in breath tests to measure gastric emptying velocity. Objectives were to investigate the impact of COMT inhibition on the recovery rate of 13 C‐sodium‐octanoate in parkinsonian patients, who received first 100 mg LD/Carbidopa (CD) and the next day 100 mg LD/CD/EN combined with 13 C‐sodium‐octanoate in each case. The recovery rate of 13 C‐sodium‐octanoate was significant higher during the LD/CD/EN–compared with the LD/CD condition. COMT inhibition combined with LD/DDI improves absorption of a co‐administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes. This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself. © 2008 Movement Disorder Society